CASTRATE RESISTANT PROSTATE CANCER
Clinical trials for CASTRATE RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATE RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATE RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers? early trial of DR-0202 begins
Disease control Recruiting nowThis early-phase study is testing an experimental drug called DR-0202 in about 96 people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the best do…
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New PARG inhibitor drug trial targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About …
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Promising combo therapy targets hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether combining two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—can slow or stop the growth of advanced prostate cancer that has spread and no longer responds to hormone therapy. About 48 men with this type of cancer…
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 01, 2026 15:57 UTC